News & Media

Take a look inside our world

Press Releases

Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on Novembe...

Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5,

Teva Releases Q3 2025 Aide Memoire

Teva Releases Q3 2025 Aide Memoire

Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement...

Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapi...

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LA

Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine...

Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI

Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy

Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy

Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare...

Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conf

Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic G...

Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1

FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Trea...

FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment

Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Reve...

Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue O
View all press releases
Previous
Next

Contacts for Media Inquiries

Kelley Dougherty

North America

+1-973-658-0237
Kelley.Dougherty@tevapharm.com

Eden Klein

Israel & Corporate

+972-3-9062645
Eden.Klein@teva.co.il

Fiona Cohen

Europe

fiona.cohen@tevaeu.com

Teva Media Assets

These proprietary media assets are available for download and are intended for non-commercial media use and research only.

Download Logo Download Teva B-Roll

Feature stories

All Access to Medicine Biologics Biosimilars Caregivers Environment Generic Medicines Global Operations Immunology Innovation Leadership Inclusion & Diversity Neuroscience Our People Patient Focus Quality Research & Development Respiratory Sustainability Wellbeing Working at Teva

3 Trends I’m Watching in Pharmaceutical Marketing and Digital

3 Trends I’m Watching in Pharmaceutical Marketing and Digital

Spreading HOPE: Teva’s Work to Improve Global Access to Medicine

Spreading HOPE: Teva’s Work to Improve Global Access to Medicine

Living With an Invisible Disability: What We All Need to Know

Living With an Invisible Disability: What We All Need to Know

Treating the Untreatable: Harnessing Biological Processes to Fight Disease

Treating the Untreatable: Harnessing Biological Processes to Fight Disease

A Passport to Career Development: A Journey with Teva's R&D Teams

A Passport to Career Development: A Journey with Teva's R&D Teams

The Neuroscience of Inclusion and Diversity: Unlocking High-Impact Team Performance

The Neuroscience of Inclusion and Diversity: Unlocking High-Impact Team Performance

Migraine at Work: How it Impacts Us All

Migraine at Work: How it Impacts Us All

What are Biologics and Biosimilars?

What are Biologics and Biosimilars?

Medical Specialists We All Need but Never See: Safety Physicians

Medical Specialists We All Need but Never See: Safety Physicians

3 Trends I’m Watching in Sustainability

3 Trends I’m Watching in Sustainability
View all stories

Connect with us on social media

Follow us on Facebook

Go to facebook.com

Follow us on Linkedin

Go to linkedin.com

Follow us on Twitter

Go to twitter.com

View our Social Media Guidelines

Learn more